ATTN: MAIL STOP PATENT APPLICATION

Susan A. Gordon

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1648
Jensen, Wayne A.) Examiner:
Lappin, Michael R.)
Rosen, David K.) <u>INFORMATION DISCLOSURE</u>
Andrews, Janet S.) <u>STATEMENT</u>
Serial No.: not yet assigned)
Serial 140 Hot yet assigned	CERTIFICATE OF MAILING
Filed: September 25, 2003	I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
,	DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO MAIL
Atty. File No.: DI-9-1	STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON
	THIS 23 DAY OF SEPTEMBER 2003.
For: "USE OF RECOMBINANT ANTIGENS	HESKA CORPORATION
TO DETERMINE THE IMMUNE) By: Dusan U. Hordor

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

STATUS OF AN ANIMAL"

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicants hereby provide the enclosed Form PTO-1449. The present application, Serial No. [not yet assigned], relies upon the previously filed application, Serial No. 09/521,738, filed March 9, 2000, for an earlier filing date. Therefore, in accordance with 37 CFR § 1.98(d), copies of all documents listed on attached Form PTO-1449 that were previously submitted to the U.S. Patent and Trademark Office or cited in Office Actions in Application Serial No. 09/521,738 are not herein provided.

Respectfully submitted,

Dated: September 25, 2003

Richard J. Stern, Ph.D. Registration No. 50,668 Heska Corporation 1613 Prospect Parkway

Fort Collins, Colorado 80525

Telephone: (970) 493-7272 Facsimile: (970) 491-9976

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 1 of 3

ATTY. DOCKET NO. DI-9-1

SERIAL NO. not yet assigned

Wayne A. Jensen, Michael R. Lappin, David K. Rosen, and Janet S. Andrews

FILING DATE September 25, 2003

GROUP

EXAM. DOCUMENT ISSUE DATE PATENTEE CLS SUP CLS							
INITIAL		NUMBER	ISSUE DATE	PATENTEE	CLS	SUB-CLS	FIL DAT
	A1	4,313,734	Feb. 2, 1982	Leuvering	23	230 B	
	A2	4,366,241	Dec. 28, 1982	Tom et al.	435	7	
	A3	4,469,787	Sep. 4, 1984	Woods et al.	435	7	
	A4	4,623,461	Nov. 18, 1986	Hossom et al.	210	445	<u>-</u>
	A5	4,632,901	Dec. 30, 1986	Valkirs et al.	435	5	
	A6	4,693,834	Sep. 15, 1987	Hossom	210	767	
	A7	4,727,019	Feb. 23, 1988	Valkirs et al.	435	5	
	A8	4,775,636	Oct. 4, 1988	Moeremans et al.	436	518	
	A9	4,853,335	Aug. 1, 1989	Olsen et al.	436	527	
	A10	4,855,240	Aug. 8, 1989	Rosenstein et al.	436	514	
	A11	4,859,612	Aug. 22, 1989	Cole et al.	436	523	
	A12	4,923,680	May 8, 1990	Nelson	422	58	
	A13	4,939,096	Jul. 3, 1990	Tonelli	435	5	
	A14	4,962,023	Oct. 9, 1990	Todd et al.	435	7	
	A15	4,965,187	Oct. 23, 1990	Tonelli	435		
	A16	4,999,163	Mar. 12, 1991	Lennon et al.	422	58	
·	A17	5,006,464	Apr. 9, 1991	Chu et al.	435	7.1	
	A18	5,120,643	Jun. 9, 1992	Ching et al.	435	7.92	
	A19	5,137,804	Aug. 11, 1992	Greene et al.	435	5	
	A20	5,141,850	Aug. 25, 1992	Cole et al.	436	525	
	A21	5,202,267	Apr. 13, 1993	Ditlow et al.	436	525	
	A22	5,202,268	Apr. 13, 1993	Kuhn et al.	436	525	
	A23	5,223,220	Jun. 29, 1993	Fan et al.	422	58	
	A24	5,256,372	Oct. 26, 1993	Brooks et al.	422	58	
	A25	5,391,272	Feb. 21, 1995	O'Daly et al.	204	153.12	
	A26	5,391,478	Feb. 21, 1995	Greene et al.	435	5	
	A27	5,356,785	Oct. 18, 1994	McMahon et al.	435	7.92	
	A28	5,418,171	May 23, 1995	Kimura et al.	436	518	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 2 of 3

ATTY. DOCKET NO. DI-9-1

SERIAL NO. not yet assigned

Wayne A. Jensen, Michael R. Lappin, David K. Rosen,

and Janet S. Andrews

FILING DATE September 25, 2003

GROUP

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLS	SUB-CLS	FIL DAT
	A29	5,541,059	Jul. 30, 1996	Chu	435	5	
	A30	5,552,276	Sep. 3, 1996	Mochida et al.	435	6	
	A31	5,561,049	Oct. 1, 1996	Vold et al.	435	7.1	
	A32	5,571,667	Nov. 5, 1996	Chu et al.	435	5	
	A33	5,591,645	Jan. 7, 1997	Rosenstein	436	514	
	A34	5,622,871	Apr. 22, 1997	May et al.	436	514	
	A35	5,656,503	Aug. 12, 1997	May et al.	436	514	
	A36	5,679,526	Oct. 21, 1997	Buechler et al.	435	7.1	
	A37	5,714,389	Feb. 3, 1998	Charlton et al.	436	514	
	A38	5,726,010	Mar. 10, 1998	Clark	435	5	
	A 39	5,726,013	Mar. 10, 1998	Clark	435	5	
	A40	5,750,333	May 12, 1998	Clark	435	5	
	A41	5,759,774	Jun. 2, 1998	Hackett et al.	435	2	
	A42	5,766,933	Jun. 16, 1998	El Shami et al.	435	287.2	
	A43	5,821,073	Oct. 13, 1998	Lee	435	7.92	
	A44	5,851,776	Dec. 22, 1998	Valkirs	435	7.1	***************************************
	A45	5,872,013	Feb. 16, 1999	Leunissen et al.	436	525	
	A46	5,888,826	Mar. 30, 1999	Ostgaard et al.	436	69	

	,	FOREIGN PATE	NT OR PUBLISHE	D FOREIGN PATENT A	APPLICATIONS		
EXAM. INITIAL		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLS	SUB-CLS	TRANS
	B1	WO 85/05451	5 Dec. 1985	PCT			
	B2	WO 99/12038	11 Mar. 1999	PCT			
	В3	0 158 746 B1	12 Jun. 1991	EP			
	B4	0 180 638 B1	13 Jan. 1993	EP		+	

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 3 of 3

ATTY. DOCKET NO. DI-9-1

SERIAL NO. not yet assigned

Wayne A. Jensen, Michael R. Lappin, David K. Rosen, and Janet S. Andrews

FILING DATE September 25, 2003

GROUP

 T 64	OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)
 C1	Clark et al., 1991, <i>JAVMA</i> , Vol. 199, No. 10, pp. 1433-1443
 C2	Dawson et al., 1998, <i>J Vet Diagn</i> , Vol. 10, pp. 315-319
 C3	Fiscus et al., 1985, <i>Am J Vet Res</i> , Vol. 46, No. 4, pp. 859-863
 C4	Fontenot et al., 1992, Journal of Clinical Microbiology, Vol. 30, No. 7, pp. 1885-1890
 C5	Hill et al., 1995, Am J Vet Res, Vol. 56, No. 9, pp. 1181-1187
 C6	Hofmann-Lehmann et al., 1995, Veterinary Immunology and Immunopathology, Vol. 46, pp. 127-137
 C7	Hoover et al., 1996, Aids Research and Human Retroviruses, Vol. 12, pp. 379-383
 C8	lkeda et al., 1998, J. Vet. Med. Sci., Vol. 60, No. 8, pp. 973-974
C9	Lau et al., 1992, Veterinary Microbiology, Vol. 31, pp. 139-146
C10	Marciani et al., 1991, <i>Vaccine</i> , Vol. 9, pp. 89-96
 C11	McCaw et al., 1998, <i>JAVMA</i> , Vol. 213, No. 1, pp. 72-75
C12	Osterhaus et al., 1989, <i>Vaccine</i> , Vol. 7, pp. 137-141
 C13	Scott et al., 1997, Feline Practice, Vol. 25, No. 4, pp. 12-19
C14	Scott et al., 1999, <i>AJVR</i> , Vol. 60, No. 5, pp. 652-658
 C15	Spencer et al., 1991, Journal of Wildlife Diseases, Vol. 27, No. 4, pp. 578-583
C16	Spencer et al., 1992, Journal of Wildlife Diseases, Vol. 28, No. 1, pp. 102-104
C17	Waner et al., 1996, <i>J Vet Diagn Invest</i> , Vol. 8, pp. 427-432
C18	Yagami et al., 1985, <i>Exp. Anim.</i> , Vol. 34, No. 3, pp. 287-293
 C19	Knapp, et al., 1999, <i>Vaccine</i> , Vol. 17, pp. 1663-1666
 C20	Bouche, et al., 1998, Journal of Virological Methods, Vol. 74, pp. 77-87
C21	Spatz, et al., 1993, <i>Virology</i> , Vol. 197, pp. 125-136
 C22	Wild, et al., 1993, <i>Vaccine</i> , Vol. 11, Issue 4, pp. 438-444
 C23	Ekins, 1989, Journal of Pharmaceutical and Biomedical Analysis, Vol. 7, No. 2, pp. 155-168
C24	Hofmann-Lehmann, et al., 1996, Clinical and diagnostic laboratory immunology, Sep., pp. 554-562
C25	Maeda, et al., 1997, <i>Virus Genes</i> , Vol. 42, No. 2, pp. 105-109
C26	Carter, et al., 1992, Virology, Vol. 190, pp. 443-448
C27	Carlson, et al., 1985, <i>Journal of Virology</i> , Vol. 55, No. 3, pp. 574-582
C28	Prud'homme, et al., 1997, <i>Can J Vet Res</i> , Vol. 61, pp. 286-291
C29	Carlson, et al., June 30, 1987, Genbank Accession No. A03701
C30	Maeda, et al., Nov. 1, 1998, EMBL Accession No. 090731
C31	Carter, et al., June 30, 1993, Genbank Accession No. B43382

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.